Interferon Alpha Treatment and Endocrine Disease

Kloke O. , Opalka B. , Niederle N. Interferon alfa as primary treatment of chronic myeloid leukemia: long-term follow-up of 71 patients observed in a single center. Leukemia 2000; 14: 389–92

Lindsay K.L. Introduction to therapy of hepatitis C. Hematology 2002; 36(5 Suppl 1): S114–20

Oberg K. The action of interferon alpha on human carcinoid tumours. Semin Cancer Biol 1992; 3: 35–41

Wong D.K. , Cheung A.M. , O'Rourke K. , Naylor C.D. , Detsky A.S. , Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312–23

Agarwala S.S. , Kirkwood J.M. Update on adjuvant interferon therapy for high-risk melanoma. Oncology (Huntingt) 2002; 16: 1177–87; discussion 1190-2, 1197

Chedin P. , Chanson P. , Duranteau L. , Guillausseau P.J. , Lubetzki J. Dysthyroidism in patients treated with interferon alpha. Presse Med 1994; 23: 1659–63

Fattovich G. , Giustina G. , Favarato S. , Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38–47

Murakami M. , Kakizaki S. , Takayama H. , Takagi H. , Mori M. Autoimmune thyroid disease induced by interferon therapy. Nippon Rinsho 1999; 57: 1779–83

Okanoue T. , Sakamoto S. , Itoh Y. . Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283–91

Marazuela M. , Garcia-Buey L. , Gonzalez-Fernandez B. . Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 1996; 44: 635–42

Rocco A. , Gargano S. , Provenzano A. . Incidence of autoimmune thyroiditis in interferon-alpha treated and untreated patients with chronic hepatitis C virus infection. Neuroendocrinol Lett 2001; 22: 39–44

Carella C. , Amato G. , Biondi B. . Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis. Horm Res 1995; 44: 110–14

Kryczka W. , Brojer E. , Kowalska A. , Zarebska-Michaluk D. Thyroid gland dysfunctions during antiviral therapy of chronic hepatitis C. Med Sci Monit 2001; 7(Suppl 1): 221–5

Cacoub P. , Renou C. , Rosenthal E. . Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Médecine Interne et Maladies Infectieuses sur le Virus de l'Hépatite C. Medicine (Baltimore) 2000; 79: 47–56

Fernandez-Soto L. , Gonzalez A. , Escobar-Jimenez F. . Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 1998; 158: 1445–8

Huang M.J. , Tsai S.L. , Huang B.Y. , Sheen I.S. , Yeh C.T. , Liaw Y.F. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin Endocrinol (Oxf) 1999; 50: 503–9

Preziati D. , La Rosa L. , Covini G. . Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995; 132: 587–93

Custro N. , Montalto G. , Scafidi V. . Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J Endocrinol Invest 1997; 20: 374–80

Hsieh M.C. , Yu M.L. , Chuang W.L. . Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 2000; 142: 431–7

Watanabe U. , Hashimoto E. , Hisamitsu T. , Obata H. , Hayashi N. The risk factors for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 1994; 89: 399–403

Murakami T. , Masumoto T. , Michitaka K. . Prediction of interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C. J Gastroenterol Hepatol 1995; 10: 528–31

Dalgard O. , Bjoro K. , Hellum K. . Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med 2002; 251: 400–6

Amenomori M. , Mori T. , Fukuda Y. . Incidence and characteristics of thyroid dysfunction following interferon therapy in patients with chronic hepatitis C. Intern Med 1998; 37: 246–52

Mazziotti G. , Sorvillo F. , Stornaiuolo G. . Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. J Endocrinol Invest 2002; 25: 624–30

Roti E. , Minelli R. , Giuberti T. . Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 1996; 101: 482–7

Carella C. , Mazziotti G. , Morisco F. . Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001; 86: 1925–9

Carella C. , Mazziotti G. , Morisco F. . The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol 2002; 146: 743–9

Papo T. , Oksenhendler E. , Izembart M. , Leger A. , Clauvel J.P. Antithyroid hormone antibodies induced by interferon-alpha. J Clin Endocrinol Metab 1992; 75: 1484–6

Fentiman I.S. , Balkwill F.R. , Thomas B.S. , Russell M.J. , Todd I. , Bottazzo G.F. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol 1988; 24: 1299–303

Ronnblom L.E. , Alm G.V. , Oberg K.E. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115: 178–83

Silvestri F. , Virgolini L. , Mazzolini A. . Development of autoimmune thyroid diseases during long-term treatment of hematological malignancies with alpha-interferons. Haematologica 1994; 79: 367–70

Vallisa D. , Cavanna L. , Berte R. , Merli F. , Ghisoni F. , Buscarini L. Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon. Acta Haematol 1995; 93: 31–5

Corssmit E.P. , Heyligenberg R. , Endert E. , Sauerwein H.P. , Romijn J.A. Acute effects of interferon-alpha administration on thyroid hormone metabolism in healthy men. J Clin Endocrinol Metab 1995; 80: 3140–4

Guerin V. , Todd I. , Hammond L.J. , Bottazzo G.F. , Pujol-Borrell R. , Feldmann M. Suppression of HLA class II expression on thyrocytes by interferon-alpha 1. Clin Exp Immunol 1990; 79: 341–5

Bottazzo G.F. , Pujol-Borrell R. , Hanafusa T. , Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 1983; ii: 1115–19

Yue S.J. , Enomoto T. , Matsumoto Y. , Kawai K. , Volpe R. Thyrocyte class I and class II upregulation is a secondary phenomenon and does not contribute to the pathogenesis of autoimmune thyroid disease. Thyroid 1998; 8: 755–63

Kawai K. , Enomoto T. , Fornasier V. , Resetkova E. , Volpe R. Differential effects of human interferon alpha and interferon gamma on xenografted human thyroid tissue in severe combined immunodeficient mice and nude mice. Proc Assoc Am Physicians 1997; 109: 126–35

Watson P.F. , Pickerill A.P. , Davies R. , Weetman A.P. Analysis of cytokine gene expression in Graves’ disease and multinodular goiter. J Clin Endocrinol Metab 1994; 79: 355–60

Grubeck-Loebenstein B. , Buchan G. , Chantry D. . Analysis of intrathyroidal cytokine production in thyroid autoimmune disease: thyroid follicular cells produce interleukin-1 alpha and interleukin-6. Clin Exp Immunol 1989; 77: 324–30

Durelli L. , Ferrero B. , Oggero A. . Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS. Neurology 2001; 57: 1363–70

Fabris P. , Betterle C. , Floreani A. . Development of type 1 diabetes mellitus during interferon alpha therapy for chronic HCV hepatitis. Lancet 1992; 340: 548

Fabris P. , Betterle C. , Greggio N.A. . Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998; 28: 514–17

Betterle C. , Fabris P. , Zanchetta R. . Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care 2000; 23: 1177–81

Wesche B. , Jaeckel E. , Trautwein C. . Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001; 48: 378–83

Oshimoto K. , Shimizu H. , Sato N. , Mori M. A case of Addison's disease which became worse during interferon therapy: [insulin secretion under hyposmolarity]. Nippon Naibunpi Gakkai Zasshi 1994; 70: 511–16

Knost J.A. , Sherwin S. , Abrams P. , Oldham R.K. Increased steroid dependence after recombinant leucocyte interferon therapy. Lancet 1981; ii: 1287–8

Gisslinger H. , Svoboda T. , Clodi M. . Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology 1993; 57: 489–95

Sakane N. , Yoshida T. , Yoshioka K. , Umekawa T. , Kondo M. , Shimatsu A. Reversible hypopituitarism after interferon alfa therapy. Lancet 1995; 345: 1305

Wilson L.E. , Widman D. , Dikman S.H. , Gorevic P.D. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum 2002; 32: 163–73